Pharmaceuticals

The French economy unexpectedly stagnated during the 2nd quarter, according to France's National Institute of Statistics and Economic Studies, which reported that France's 2nd quarter economic growth rate was 0% and that consumer spending fell 0.9%. The news is troubling because France is the...

Merlin Nexus and New Leaf Venture Partners (NLV Partners), stockholders in Icagen, Inc. (Nasdaq: ICGN), submitted a second letter to the Icagen Board contesting the company's planned acquisition by Pfizer Inc (NYSE: PFE). According to a July 20, 2011 press announcement, Pfizer plans to purchase the...

Citi is maintaining its Buy rating and its $82 price target on Watson Pharmaceuticals (NYSE: WPI) in light of expected margin expansion from the company. Says Citi, in its report, “We project Concerta sales of $132M/$156M in 3Q11/4Q11 & Lipitor sales of $345M in 4Q11 (Nov. '11 launch) to fuel...

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. (NYSE: PRX) and Par Pharmaceutical Companies, Inc and Actavis South Atlantic LLC and Actavis, Inc.. The lawsuits were...

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced shipping of its Morphine Sulfate Oral Solution product. The company received approval from the U.S. Food and Drug Administration for its 505(b)(2) New Drug Application (NDA) on June 23, 2011. Sales of Morphine Sulfate Oral...

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 7,994,197, titled "Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile." The patent,...

On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Cummins (NYSE: CMI) is an “unbelievable manufacturer with a big backlog. I think you should buy some more at these levels." Cramer said that he has “disliked Merck (NYSE: MRK), but it yields 5% and I'm changing my tune. I'm a...

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the companies' BYDUREON™ (exenatide extended-release for injectable suspension) resubmission. The FDA...

Shares of Sanofi (NYSE: SNY) are lower on the session by 6.01%, currently trading at $32.06. The stock has been moving largely lower over the past two months and is currently trading below the 50-day moving average. Options traders are buying puts on the name today. A short while ago the 2011...

Congratulations, you've just lived through the sixth-worst day in the history of the U.S. stock market. The Dow Industrials fell 634 points on Monday in response to Standard & Poor's downgrade of the United States' credit rating, and two days later the volatility continues. After a day like...

Forest Laboratories, Inc. (NYSE: FRX) commented on today's report by leading proxy advisory service Institutional Shareholder Services, recommending that shareholders vote the WHITE proxy card to elect all ten of Forest's director nominees at the Company's Annual Meeting of Shareholders, which will...

Shares of Adolor (NASDAQ: ADLR) are higher on the session by 0.45%, trading at $2.22. Overall call volume is now running at 7.78x the daily average, with 0% of all calls traded being purchases on the offer. 3,035 contracts have traded on the session so far. Adolor Corporation is a...

Zacks Small Cap Research has published a report on Depomed (NASDAQ: DEPO) upgrading the company's stock from Neutral to Outperform. In the report, Zacks wrote, "However, Depomed, with its solid cash position ($164 million as of June 2011), two approved drugs in Glumetza and Gralise, and our...

Zacks Investment Research has upgraded Depomed (NASDAQ: DEPO) from Neutral to Outperform with a $10 price target.

Piper Jaffray is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), upgrading ENDP to Overweight from Neutral. In its report, Piper Jaffray writes, "We are upgrading Endo to Overweight from Neutral and raising our price target to $46 from $44. With management guiding to a 2011 EPS...